Browsing by Subject "Dolutegravir"
Now showing items 1-5 of 5
-
Adherence to antiretroviral therapy before and after substitution to Dolutegravir and associated factors among pregnant and postpartum mothers at the MUJHU supported facilities in Kampala - Uganda.
(Makerere University, 2023-01-19)Introduction: In 2020, the Uganda Ministry of health rolled out the use of dolutegravir based ART regimens as the preferred first line ART for all people living with HIV including the pregnant and postpartum mothers. Despite ... -
Development and validation of an HPLC-UV method for the simultaneous determination of Efavirenz and Dolutegravir in human plasma
(Makerere University, 2022-12)Background: Although HIV/AIDS possess a challenge, global efforts have been mounted to address the epidemic. These include the massive role out of anti-retroviral therapy (ART) globally. To date either efavirenz or ... -
Prevalence and factors associated with Dolutegravir-related hyperglycemia among children and adolescents <18 years attending Soroti Regional Referral and Lira Regional Referral Hospitals
(Makerere University, 2023-07)Background: The World Health Organization (WHO) recommended Dolutegravir (DTG) as the preferred anchor drug in first and second line Anti-Retroviral Treatment (ART) regimens owing to its high genetic barrier to resistance, ... -
Prevalence and factors influencing suboptimal adherence to dolutegravir-based regimens among adult patients at Joint Clinical Research Center, Lubowa
(Makerere University, 2022-12)Background: An estimated 37.7 million people are living with HIV globally with the majority being in sub-Saharan Africa. There is a need to address suboptimal adherence to prevent dolutegravir resistance in order to maintain ... -
Prevalence of neuropsychiatric adverse events and associated factors among adult patients on Dolutegravir attending Mulago ISS clinic.
(Makerere University, 2022-02)Introduction: Dolutegravir (DTG) is a second-generation integrase strand transfer inhibitor that is recommended by World Health Organization for use as the preferred first line and second line anti-retroviral regimen ...